Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 33, Issue 2, Pages 286-288Publisher
WILEY-BLACKWELL
DOI: 10.1002/hed.21299
Keywords
cutaneous; squamous cell carcinoma; SCC; metastatic; cetuximab
Categories
Ask authors/readers for more resources
Background. Head and neck cutaneous squamous cell carcinoma (SCC) metastatic to lymph nodes is commonly treated with surgery plus radiotherapy. Methods. We present the case of a 92-year-old man with cutaneous SCC metastatic to the neck (7 cm) who was treated with primary cetuximab and has had a durable complete response for 7 months. Because of his age, comorbidities, and unresectable neck lymphadenopathy, he received primary cetuximab. He received a 400 mg/m(2) loading dose and a 250 mg/m2 weekly dose for 3 months and then had to discontinue as a result of other unrelated medical issues. Results. The patient had a complete response by 6 weeks. Seven months after discontinuing cetuximab, he continues to have a complete response. Conclusions. Primary cetuximab for cutaneous SCC metastatic to lymph nodes is an area that bears further investigation because of its apparent efficacy and excellent toxicity profile. (C) 2009 Wiley Periodicals, Inc. Head Neck 33: 286 288, 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available